Barclays PLC Kinnate Biopharma Inc. Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.24 - $2.66 $857 - $1,018	-383 Reduced 2.63%	14,185 $38,000
Q2 2023 Aug 03, 2023	SELL	$2.33 - $6.84 $34,616 - $101,621	-14,857 Reduced 50.49%	14,568 $44,000
Q1 2023 May 04, 2023	BUY	$3.46 - $7.98 $17,434 - $40,211	5,039 Added 20.66%	29,425 $183,000
Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $47,140 - $109,246	8,962 Added 58.1%	24,386 $149,000
Q3 2022 Nov 03, 2022	SELL	$9.86 - $15.76 $2,248 - $3,593	-228 Reduced 1.46%	15,424 $185,000
Q2 2022 Aug 12, 2022	BUY	$7.43 - $13.0 $116,294 - $203,476	15,652 New	15,652 $197,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.